{"altmetric_id":4686826,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Anthera Pharmaceuticals"],"first_seen_on":"2015-10-28T12:15:05+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1413314544,"links":["http:\/\/www.clinicaltrials.gov\/show\/NCT01130246","http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01130246"],"nct_id":"NCT01130246","pubdate":"2010-04-19T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome","type":"clinical_trial_study_record"},"altmetric_score":{"score":3.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3.25},"context_for_score":{"all":{"total_number_of_other_articles":4755595,"mean":5.7068799069093,"rank":1102897,"this_scored_higher_than_pct":76,"this_scored_higher_than":3630628,"rank_type":"exact","sample_size":4755595,"percentile":76},"similar_age_3m":{"total_number_of_other_articles":180351,"mean":9.847478902135,"rank":51627,"this_scored_higher_than_pct":70,"this_scored_higher_than":127978,"rank_type":"exact","sample_size":180351,"percentile":70},"this_journal":{"total_number_of_other_articles":12383,"mean":3.8162440639638,"rank":3273,"this_scored_higher_than_pct":73,"this_scored_higher_than":9090,"rank_type":"exact","sample_size":12383,"percentile":73},"similar_age_this_journal_3m":{"total_number_of_other_articles":633,"mean":3.6384936708861,"rank":140,"this_scored_higher_than_pct":77,"this_scored_higher_than":493,"rank_type":"exact","sample_size":633,"percentile":77}}},"demographics":[],"counts":{"total":{"posts_count":4},"facebook":{"unique_users_count":1,"unique_users":["100000628338767"],"posts_count":2},"wikipedia":{"unique_users_count":2,"unique_users":["en:32790202","en:32782638"],"posts_count":2}},"posts":{"facebook":[{"title":"VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With...","url":"https:\/\/www.facebook.com\/100000628338767\/posts\/708796089151329","license":"public","citation_ids":[4686826],"posted_on":"2014-02-01T04:19:56+00:00","author":{"name":"Jainendra Upadhyay","url":"https:\/\/www.facebook.com\/100000628338767","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/100000628338767\/picture","id_on_source":"100000628338767"}},{"title":"VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With...","url":"https:\/\/www.facebook.com\/100000628338767\/posts\/708796009151337","license":"public","citation_ids":[4686826],"posted_on":"2014-02-01T04:19:24+00:00","summary":"Http:\/\/www.clinicaltrials.gov\/show\/NCT01130246","author":{"name":"Jainendra Upadhyay","url":"https:\/\/www.facebook.com\/100000628338767","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/100000628338767\/picture","id_on_source":"100000628338767"}}],"wikipedia":[{"title":"Varespladib","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=629614168#altmetric_citation_5","license":"public","citation_ids":[4686826],"posted_on":"2014-10-14T19:22:24+00:00","summary":"Elevated serum levels of sPLA2 have been observed in sickle-cell patients preceding and during ACS episodes.","page_url":"http:\/\/en.wikipedia.org\/?curid=32790202","wiki_lang":"en","author":{"name":"72.244.116.122","url":"http:\/\/en.wikipedia.org\/wiki\/Special:Contributions\/72.244.116.122"}},{"title":"Varespladib methyl","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=445414774#altmetric_citation_8","license":"public","citation_ids":[4686826],"posted_on":"2011-08-17T23:15:22+00:00","summary":"Varespladib methyl (also known as A-002, formerly LY333013 and S-3013) is a secretory phospholipase A2 (sPLA2) inhibitor formerly under development by Anthera Pharmaceuticals as a treatment for acute coronary syndrome (ACS).","page_url":"http:\/\/en.wikipedia.org\/?curid=32782638","wiki_lang":"en","author":{"name":"Blysful","url":"http:\/\/en.wikipedia.org\/wiki\/User:Blysful"}}]}}